NantKwest Inc. (NK) Director John C. Thomas Sells 6,168 Shares of Stock
NantKwest Inc. (NASDAQ:NK) Director John C. Thomas sold 6,168 shares of the firm’s stock in a transaction that occurred on Friday, November 25th. The shares were sold at an average price of $7.50, for a total value of $46,260.00. Following the completion of the sale, the director now owns 309,621 shares in the company, valued at $2,322,157.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of NantKwest Inc. (NASDAQ:NK) opened at 6.83 on Wednesday. The company’s market capitalization is $562.62 million. NantKwest Inc. has a 1-year low of $5.43 and a 1-year high of $18.74. The stock’s 50 day moving average price is $6.84 and its 200 day moving average price is $7.14.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/30/nantkwest-inc-nk-director-john-c-thomas-sells-6168-shares-of-stock.html.
A number of equities analysts have issued reports on the company. Zacks Investment Research raised NantKwest from a “hold” rating to a “buy” rating and set a $8.50 price target for the company in a research note on Saturday, November 19th. Canaccord Genuity reaffirmed a “buy” rating and set a $18.00 price target on shares of NantKwest in a research note on Friday, August 19th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $23.00 price target (down from $32.00) on shares of NantKwest in a research note on Wednesday, August 17th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $17.70.
A number of large investors have recently added to or reduced their stakes in NK. JPMorgan Chase & Co. increased its stake in NantKwest by 2.2% in the first quarter. JPMorgan Chase & Co. now owns 152,196 shares of the company’s stock worth $1,251,000 after buying an additional 3,309 shares during the last quarter. Bank of New York Mellon Corp increased its stake in NantKwest by 39.4% in the second quarter. Bank of New York Mellon Corp now owns 78,443 shares of the company’s stock worth $487,000 after buying an additional 22,155 shares during the last quarter. California State Teachers Retirement System increased its stake in NantKwest by 144.2% in the second quarter. California State Teachers Retirement System now owns 34,954 shares of the company’s stock worth $217,000 after buying an additional 20,643 shares during the last quarter. Swiss National Bank increased its stake in NantKwest by 16.8% in the second quarter. Swiss National Bank now owns 42,450 shares of the company’s stock worth $264,000 after buying an additional 6,100 shares during the last quarter. Finally, Emerald Acquisition Ltd. bought a new stake in NantKwest during the second quarter worth $228,000. 24.23% of the stock is currently owned by institutional investors.
NantKwest, Inc, formerly Conkwest, Inc, is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases.
Receive News & Stock Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related stocks with our FREE daily email newsletter.